continuous glucose monitoring

Enhancing Glycemic Control in Non-Insulin-Treated Type 2 Diabetes with Continuous Glucose Monitoring: New Evidence from the CONNECT Trial

By MedXY 10/24/2026

The CONNECT trial demonstrates that continuous glucose monitoring (CGM) significantly improves glycemic control in adults with non-insulin-treated type 2 diabetes managed in primary care, reducing HbA1c levels and hyperglycemia risk without increasing hypoglycemia.

Clinical Updates Diabetes & Endocrinology news

Efficacy and Safety of the twiist Automated Insulin Delivery System in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of the twiist-T2D Pivotal Trial and Related Evidence

By MedXY 10/16/2026

The twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.

Diabetes & Endocrinology Gastroenterology news

Optimizing Insulin Therapy with Continuous Glucose Monitoring in Nocturnal Parenteral Nutrition Patients

By MedXY 10/15/2026

Continuous glucose monitoring-guided insulin optimization improves glycemic control and nutritional status in insulin-treated adults receiving long-term nocturnal parenteral nutrition, reducing hyperglycemia and associated complications.

Diabetes & Endocrinology news

Evaluating Beta Cell Function in Preclinical Type 1 Diabetes Using CGM-Derived Disposition Index

By MedXY 10/14/2026

A novel CGM-derived disposition index reliably estimates beta cell function in individuals with islet autoimmunity without insulin therapy, predicting glycemic deterioration one year later.

Diabetes & Endocrinology news

Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutic Glucura Combined with CGM Shows Superior 6-Month Outcomes

By MedXY 10/07/2026

A randomized trial demonstrates that adding the digital therapeutic glucura to intermittent CGM and standard care significantly improves HbA1c, weight loss, and mental health in non-insulin-treated type 2 diabetes patients over six months.

Diabetes & Endocrinology news

Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutics Combined with CGM Show Superior Outcomes

By MedXY 10/05/2026

A 6-month RCT in non-insulin-treated type 2 diabetes demonstrates that combining the digital therapeutic glucura with CGM significantly improves HbA1c, weight, and patient well-being beyond CGM and standard care alone.

Diabetes & Endocrinology news OB/GYN & Women's Health

Early Pregnancy Glycemic Testing Enhances Gestational Diabetes Prediction: Insights from the GO MOMs Study

By MedXY 10/05/2026

In early pregnancy, adding oral glucose tolerance testing or continuous glucose monitoring to clinical factors improves prediction of gestational diabetes mellitus but not large-for-gestational-age births.

Diabetes & Endocrinology Nephrology news

Worsening Time in Range as a Predictor of Microvascular Complications in Type 1 Diabetes: Insights from a 5-Year Real-World Study

By MedXY 09/26/2026

A 5-year real-world cohort study reveals that declines in CGM-derived time in range correlate with increased microvascular complications in type 1 diabetes, offering prognostic value beyond HbA1c.

Diabetes & Endocrinology news

Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM Study

By MedXY 09/21/2026

This study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualized management based on CGM data.

Clinical Updates Diabetes & Endocrinology news

Continuous Glucose Monitoring Using the FreeStyle Libre Pro iQ in Presymptomatic Type 1 Diabetes: Advancements in Early Detection and Risk Stratification

By MedXY 09/11/2026

This review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications for clinical practice.

Diabetes & Endocrinology news

Disentangling Fear and Hypoglycemia Metrics in Type 1 Diabetes: Insights from a 12-Month Diabetes Technology Study

By MedXY 09/09/2026

This 12-month analysis in adults with type 1 diabetes using advanced diabetes technology reveals that fear and perceived hypoglycemia frequency do not straightforwardly relate to continuous glucose monitoring metrics, highlighting complex drivers beyond glycemic data.

Diabetes & Endocrinology news Pediatrics

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Glucose Metabolism in Youths with Cystic Fibrosis: Insights from Continuous Glucose Monitoring

By MedXY 09/04/2026

This study demonstrates that initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in children and adolescents with cystic fibrosis improves continuous glucose monitoring (CGM) metrics, correlating with better clinical outcomes.

Clinical Updates Diabetes & Endocrinology news

Glucose in Motion: Insights into Temporal Patterns of Glycemic Control in Real-World Diabetes Management

By MedXY 08/18/2026

This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.

Clinical Updates Diabetes & Endocrinology Internal Medicine news

Enhancing Internal Medicine Resident Competency in Diabetes Care: Comparing Experience-Based and Traditional Continuous Glucose Monitoring Curricula

By MedXY 08/15/2026

Experience-based continuous glucose monitoring (CGM) curricula significantly improve internal medicine residents' confidence in applied patient care skills compared to traditional approaches, supporting hands-on CGM training integration in residency programs.

Diabetes & Endocrinology news

Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice

By MedXY 08/13/2026

This study reveals significant HbA1c and glucose discrepancies, especially in Black individuals, and introduces a personalized HbA1c correction (pA1C) that enhances diabetes management across racial groups.

Diabetes & Endocrinology news Public Health

Prior Authorization Suspension Boosts Access to Diabetes Technology and Improves Glycemic Control in Underserved Populations

By MedXY 08/05/2026

Suspension of prior authorization requirements led to increased access to CGM and insulin pumps and significant HbA1c improvement in type 1 diabetes patients in a safety net clinic, highlighting benefits of reducing administrative barriers.

Diabetes & Endocrinology news Pediatrics

Declining Trends in Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Youth with Type 1 Diabetes Over Two Decades

By MedXY 07/04/2026

A population-based study reveals a significant reduction in impaired awareness of hypoglycemia and severe hypoglycemia in youth with type 1 diabetes from 2002 to 2024, indicating substantial progress in diabetes care and the ongoing need for routine screening.

Cardiology Diabetes & Endocrinology news

Continuous Glucose Monitoring-Derived Time in Range Predicts Longitudinal Changes in Arterial Stiffness in Type 2 Diabetes

By MedXY 07/01/2026

This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascular risk management.

Diabetes & Endocrinology Nephrology news

Continuous Glucose Monitoring and Survival Benefits in Diabetic Veterans on Dialysis: Insights from a Nationwide Cohort

By MedXY 07/01/2026

Among U.S. veterans with diabetes on dialysis, continuous glucose monitoring (CGM) use was associated with significantly lower mortality risk compared to non-CGM use, highlighting CGM's potential to improve survival in this high-risk population.

Diabetes & Endocrinology Gastroenterology news

Preservation of Islet Function and Glycaemic Control After Total Pancreatectomy with Islet Autotransplantation: Insights From Continuous Glucose Monitoring

By MedXY 06/28/2026

This study demonstrates that nearly half of islet secretory function is preserved following total pancreatectomy with islet autotransplantation (TPIAT), independent of preoperative glycaemic status or prior pancreatic surgery. Continuous glucose monitoring reveals meaningful correlations between islet function and glycaemic control post-TPIAT.